Zura Bio Ltd (ZURA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for autoimmune and inflammatory diseases. The reporting period covers the three months ended March 31, 2026. The Company is classified as an Emerging Growth Company and a Smaller Reporting Company. Its lead product candidate, tibulizumab, is currently in Phase 2 clinical trials for hidradenitis suppurativa (HS) and systemic sclerosis (SSc).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(24.2) million | $(17.4) million |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.19) |
| Operating Expenses | $25.5 million | $19.3 million |
| Cash and Cash Equivalents (End of Period) | $225.6 million | $170.6 million |
| Accumulated Deficit | $(248.8) million | $(173.3) million |
| Net Cash Used in Operating Activities | $(18.9) million | $(11.1) million |
| Net Cash Provided by Financing Activities | $135.1 million | $5.2 million |
Material Changes vs. Prior Period
- Equity Financing: In February 2026, the Company completed an equity offering, selling 21.2 million Class A Ordinary Shares and pre-funded warrants for 1.8 million shares. Net proceeds were approximately $134.6 million, significantly boosting liquidity compared to the prior year.
- Operating Expenses: Total operating expenses increased by 32% ($6.2 million) year-over-year.
- R&D Expenses: Increased 41% to $14.7 million, driven by a $3.4 million increase in costs for the tibulizumab HS Phase 2 trial and a $0.4 million increase for the SSc Phase 2 trial.
- G&A Expenses: Increased 22% to $10.8 million, primarily due to higher compensation costs and professional fees.
- Share-Based Compensation: Total expense increased to $5.0 million from $3.6 million, including a $1.5 million charge related to the modification of equity awards for a departing executive.
- Interest Income: Decreased by $0.5 million to $1.3 million due to lower interest rates and a lower average cash balance for the majority of the quarter prior to the equity offering.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash and cash equivalents ($225.6 million) are sufficient to fund operations through at least the end of 2028.
- Clinical Milestones:
- TibuSHIELD (HS): Topline results expected in Q4 2026.
- TibuSURE (SSc): Topline results expected in H1 2027.
- Risks: The Company has no approved products and expects to incur significant losses for the foreseeable future. Key risks include the failure of clinical trials, inability to secure additional financing, reliance on third-party manufacturers, and potential inability to achieve profitability.
- Contingent Payments: The Company has significant potential future obligations under license agreements with Lilly (tibulizumab and torudokimab) and Pfizer (crebankitug), including development milestones totaling up to $379 million and sales milestones up to $1.4 billion, though none are currently due.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $18.9 million quarterly operating cash burn against the $225.6 million cash balance to confirm the 2028 runway estimate.
- Clinical Trial Progress: Monitor enrollment and safety data for the TibuSHIELD and TibuSURE Phase 2 trials, as delays or negative data would materially impact valuation.
- Equity Dilution: Review the impact of the February 2026 offering (21.2M shares + 1.8M warrants) on existing shareholder ownership and future dilution from the ATM program ($114M remaining).
- Licensing Obligations: Assess the financial impact of potential milestone payments to Lilly and Pfizer upon successful clinical or regulatory events.
- Executive Compensation: Note the $1.5 million one-time share-based compensation expense related to the separation agreement with a former executive.